Source: Annual Congress 2010 - New treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Studies suggest that orally administered guaifenesin thins lower respiratory tract secretions but few have examined its effects on mucociliary clearance (MCC). The current study was designed to assess the acute effect of a single dose of guaifenesin (Mucinex 1200mg) vs. placebo on MCC in healthy adults (n=8). MCC was measured by gamma camera analysis of the rate of removal from the lung of inhaled, deposited radioactive particles (Tc99m-sulfur colloid) one hour following oral administration of guaifenesin or placebo. Retention data over the 3 hour measurement period showed a trend (p = 0.07) for enhanced clearance for drug vs. placebo between 90-180 minutes, average clearance = 12.1 vs. 8.7% respectively. However, the enhanced clearance was predicted by a significant difference in the initial deposition pattern between drug and placebo, increased skew of the number pixel vs. counts/pixel distribution following guaifenesin (p = 0.025). Furthermore, the difference in skew between drug and placebo correlated significantly with the peak blood concentration of guaifenesin on the drug day, r = 0.86, p = 0.007. These data suggested that the drug had an effect on airway secretions during the hour between drug administration and radiotracer inhalation. When the drug/placebo was administered immediately after radiotracer inhalation (n=4), clearance rate through the initial 30 minutes from the central, bronchial region tended to be twice as fast for drug vs. placebo (p=0.07). This enhanced clearance in large airways within 30 min post dose by guaifenesin may occur via vagal stimulation of MCC (gastro-pulmonary reflex). Supported by Reckitt Benckiser, Inc.

Rating:

Share or cite this content

Citations should be made in the following way:
W. Bennett, A. Kala, K. Zeman, J. Wu, A. Henderson, H. Albrecht, G. Solomon (Chapel Hill, Parsippany, United States Of America). Effect of oral guaifenesin (Mucinex 1200mg) on mucociliary clearance from the lungs of healthy non-smoking adults. Eur Respir J 2010; 36: Suppl. 54, 1178

Member's Comments

No comment yet.

Related content which might interest you: Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012 Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007 Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002 Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003 Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017 Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Effect of ambroxol on whole lung mucociliary clearance in sheep. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Pharmacodynamics (PD) of low and high strength budesonide plus formoterol (BF) Spiromax® and BF Turbuhaler® in healthy volunteers (HV) Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Effect of codeine (30mg) with paracetamol (650mg) on post bronchoscopy coughing –an open labeled placebo control trial Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease Year: 2019 Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006 The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Evaluation of long-term safety, growth and efficacy of fluticasone propionate 100mcg bd compared with sodium cromoglycate 5mg qds in asthmatic children aged 12-47 months Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002